Serum glycoprotein hormone alpha subunit, hormone receptors and disease stage in patients with breast cancer. by MacFarlane, I. A. et al.
Br. J. Cancer (1980) 42, 645
SERUM GLYCOPROTEIN HORMONE a SUBUNIT, HORMONE
RECEPTORS AND DISEASE STAGE IN PATIENTS WITH
BREAST CANCER
I. A. MAcFARLANE*, D. BARNES*, J. M. T. HOWATt, R. SWINDELLt,
P. DURNINGt, C. G. BEARDWELL*, H. BUSH§ AND R. A. SELLWOODt
From the *Department of Endocrinology, tMedical Statistics and §C.R.C. University
Department of Medical Oncology, Christie Hospital and the tDepartment ofSurgery,
University Hospital ofSouth Manchester, Manchester
Received 15 April 1980 Accepted 11 August 1980
Summary.-The concentration ofthe common a subunit ofthe glycoprotein hormones
was high in the serum of 21/56 (38o%) of premenopausal patients and 22/106 (21%) of
postmenopausal patients with primary breast cancer, at the time of presentation.
7/59 (12%) of patients with benign disease also had high a subunit levels. Tumour
cytosol oestrogen and progesterone receptor status was determined in 80% of the
patients with cancer, and there was a trend towards higher a levels in patients
without receptors, but this was not statistically significant. In the premenopausal
patients with cancer there was a significant correlation between a subunit level and
disease stage, R=0.47, P=0.0001, but not in the postmenopausal patients. In view of
the correlation with disease stage, high levels of a subunit in premenopausal patients
with breast cancer at presentation with the primary tumour may indicate poor
prognosis.
THE COMMON ax subunit of the glyco-
protein hormones (thyroid-stimulating
hormone-TSH; follicle-stimulating hor-
mone FSH; luteinizing hormone LH,
and chorionic gonadotrophin hCG) has
been found in breast-tumour cultures
(Cove et al., 1979; Miller et al., unpubl.).
Immunoperoxidase staining has demon-
strated the presence of oa subunit in histo-
logical specimens of breast carcinomas,
and lymph-node metastases found at the
initial operation are said to be common in
patients with ay subunit-positive primary
tumours (Walker, 1978).
Increased concentrations of oa subunit
have been found in the serum of persons
with various benign and malignant con-
ditions (Dosogne-Guerin et al., 1978;
Braunstein et al., 1979) and we report here
a study of serum a subunit levels in a
large consecutive series of patients pre-
senting with primary breast cancer, and
compare them with oa subunit levels in
patients with benign breast disease and a
normal control population.
In order to define the importance of
serum oa subunit measurement in our
breast-cancer patients, we have correlated
oa levels with the tumour hormone-
receptor status and disease stage at re-
moval of the primary tumour, both fac-
tors known to influence patient survival
(Say & Donegan, 1974; Hahnel et al.,
1979).
MATERIALS AND METHODS
Patients and controls
Breast cancer.-162 consecutive patients
with operable breast cancer attending the
Breast Clinic from June 1977 to August 1978
were studied. There were 56 premenopausal
patients, median age 42-5 yrs (range 26-50)
and 106 postmenopausal patients, median age
61 yrs (range 33-82).
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Benign breast disease.-59 consecutive
patients attending the Breast Clinic from
October 1978 to March 1979 with benign
breast lumps were studied. There were 46
premenopausal patients, median age 36 yrs
(range 17-51) and13postmenopausalpatients,
median age 53 yrs (range 46-69).
Controls.-112 female blood donors and
healthy female hospital personnel served as
controls. There were 56 premenopausal
women, median age 25 (range 17-51) and
56 postmenopausal women, median age 54
(range 47-74). In a further 8 premenopausal
controls, blood was taken several days before
and several days after ovulation, ovulation
being confirmed by LH and FSH peaks.
In all patients histological proof of the
diagnosis was obtained. Blood was taken
from 147 of the cancer group and 17 of the
benign group before surgical removal of the
tumour. In the remaining patients blood was
taken within 24h ofsurgery. Serumwasstored
at -20°C before measurement, by radio-
immunoassay, of of subunit concentration
(ng/ml). Postmenopausal women were defined
as having amenorrhoea for 6 months and
serum FSH levels >20 mu/l.
Serum axsubunit assay
This was performed by double antibody
radioimmunoassay using o-TSH standard
and its antibody as previously described
(MacFarlane et at., 1979). The lower limit of
detection was 0 5 ng/ml ofserum.
Breast cancer hormone receptor assay
In 40 of the premenopausal patients with
cancer the cytoplasmic oestrogen receptor
activity (REc) and the cytoplasmic proges-
terone receptor activity (RPc) were deter-
mined in the primary tumours. In 27 ofthese
40 premenopausal patients, the nuclear
oestrogen receptor activity (REN) was also
estimated. In the postmenopausal patients
with cancer, 91 had the REC estimated, 89
had the RPC estimated, and 41 had the REN
activity estimated. The hormone receptors
were estimated by previously published
methods: REC and RPc (Barnes et al., 1977);
REN (Barnes et al., 1979).
Disease staging in breast-cancer patients
Tumours were grouped into stages (I-IV)
taking into account the tumour size and the
axillary-node status, the latter being con-
firmed by histological examination (Harmer,
1978).
RESULTS
The of subunit concentrations in the 3
groups (cancer, benign and controls) are
displayed in Fig. 1 (premenopausal) and
Fig. 2 (postmenopausal). In the premeno-
pausal women, median oc subunit levels
and ranges were as follows: breast cancer
1-05 ng/ml (0.4-200); benign disease 0 95
ng/ml (0.4-22) and controls 0-8 ng/ml
(0.4-4 3). Taking 2-3 ng/ml as the upper
limit of normal (defined as the 95% con-
fidence limit in the premenopausal con-
trols), there were 21/56 (38%) cancer
patients, 6/46 (13%) benign patients and
2/56 normals with high cx levels. In the
premenopausal patients with breast can-
cer, ox subunit levels were statistically sig-
nificantly higher than in the premeno-
pausal controls (P=0 037; Mann-Whitney
U test). There was no statistically signifi-
cant difference in ox level between the pre-
menpausal patients with benign breast
disease and the premenopausal controls
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FiG. 1.-Serum a subunit levels in premeno-
pausal patients and control subjects.
(-- -- upper 95% limit of normal in con-
trols.) Cancer vs control, P = 0-037.
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In 8 premenopausal controls, serial
measurement of of subunit at ovulation
revealed acute elevations of as subunit. In
3 patients the peak ox subunit level ex-
ceeded 5 ng/ml.
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FIG. 2.-Serum oa subunit levels in postmeno-
pausal patients and control subjects.
(---- upper 95% limit of normal in con-
trols.)
(P= 0.48) and those with breast cancer
(P = 0-22).
In the postmenopausal women median
o subunit levels and ranges were as
follows: breast cancer 5-7 ng/ml (0-4-24);
benign disease 4 ng/ml (1-9.6) and con-
trols 4-4 ng/ml (1-4-10). Taking 9-5 ng/ml
as the upper limit of normal (defined as
the 95% confidence limit in the postmeno-
pausal controls) there were 22/106 (21%)
cancer patients, 1/13 benign patients and
2/56 controls with high a subunit levels.
Comparing the 3 postmenopausal groups
(cancer, benign and controls) there were
no statistically significant differences in
cx levels (P > 0-18).
cx Subunit levels and hormone receptor
status in breast cancer patients
Median oc subunit concentrations and
ranges in the patients with breast cancer,
divided into groups according to hormone
receptor status, are displayed in Table I.
Comparing ax levels in the following
groups:
REc+ vs REc-,
RPc+ vs RPc-,
REN+ vs REN-,
REc+, RPc+ vs REc-, RPc-,
REc+, RPc+, REN+ vs REc-, RPc-,
REN,
divided into pre- and postmenopausal
patients, there was no statistically signifi-
cant difference, P> 0 1. There was, how-
ever, a trend towards higher ox levels in
pre- and postmenopausal patients without
REC and RPC. This trend was also seen in
premenopausal patients without REN but
not in postmenopausal patients without
REN receptors.
cx Subunit levels and disease stage in the
patients with breast cancer
Median ax subunit concentrations and
ranges in the different stages of breast
cancer are displayed in Table II. In the
premenopausal patients more advanced
disease was associated with higher cx sub-
unit levels, R=0-47, P=0-0001 (Spear-
TABLE I.-Hormone receptor status and serum ax subunit concentrations (ng/ml, median
and ranges) in patients with breast cancer
REC+ REc-
REC+ REc- RPc+ RPc-
REc+ REc- RPC+ RPc- REN+ REN- RPc+ RPc- REN+ REN-
Premenopausal 0-9 1-2 0-7 1-5 0-9 1-6 0-9 1-4 0-8 1-5
(0-4-14) (0-4-200) (0-4-5-2) (0-4-200) (0-4-14) (0-4-4-7) (0-4-5-2) (0.4-15) (0-4-5-2) (0-4-4-7)
No. ofpatients 20 20 19 21 15 12 15 16 14 9
Postmenopausal 5-2 5-8 5-1 5-8 6-7 4-4 5-1 5-8 6
(0-4-19) (0-4-15) (0-7-19) (0-4-15) (1-3-19) (2-1-13) (0-7-19) (0-4-15) (2-6-19)
No. ofpatients 45 46 30 59 20 21 26 40 11
5-2
(2-1-13)
17
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20
1- -I. A. MACFARLANE ET AL.
TABLE II. Disease stage and serurn o subunit concentrations (ng/ml, median and ranges)
in patients with breast cancer
Stage I Stage II Stage III Stage IV
Premenopausal 0 4 1.1 2-4 6-6
(0-4-5-2) (0 4-14) (0 5-200) (4-3-8 4)
No. of patients 11 35 6 3
Postmenopausal 5.9 5.3 5-6 6-4
1-5-13) (0-7-15) (1-2-14) (0-4-19)
No. of patients 12 60 23 9
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FIG. 3.- Serum a subunit levels (with me(lian)
in premenopausal patients with breast
cancer according to (lisease stage.
mann's rank correlation). Individual a
subunit conceiitrations in the 4 stages in
the premenopausal patients are shown in
Fig. 3.
In the postmenopausal patients there
was no correlation between of level and
disease stage, R = 0 l, P > 0 3.
DISCUSSION
In this study we have found that 21/56
(38%) premenopausal and 22/106 (210%)
postmenopausal patients presenting with
primary breast cancer have serum a sub-
unit levels above the defined upper limit
of normal in controls. Two other recent
studies of patients with breast cancer
found 35/116 (300o) (Dosogne-Guerin et
al., 1978) and 10/104 (10%) (Cove et al.,
1979) with high ax levels. The differences in
incidence of high a levels in these studies
may in part be due to different definitions
ofthe normal range.
Comparing the premenopausal cancer
patients with the premenopausal control
population we found that ax subunit levels
were significantly higher in the cancer
group. The ages of the premenopausal
patients with cancer were higher than
those of the premenopausal controls, but
this was not the cause of the increased
oasubunit levels in the cancer group. There
was no correlation between ax subunit
levels and age in the premenopausal
patients with cancer (r=0'06, P > 0 5) or
in the premenopausal controls (r= 0a12,
P > 0.2). There was no significant differ-
ence in a level on comparing the post-
menopausal cancer patients with the post-
menopausal patients with benign disease
and the postmenopausal controls. In a
previous study ofpatients with metastatic
melanoma we also found that oa subunit
levels were more frequently high in pre-
menopausal than in postmenopausal
patients (MacFarlane et al., 1979). It is
possible that the lack of significant differ-
ence in oa level between the postmeno-
pausal patients with breast cancer and
the postmenopausal controls may reflect
the higher normal base line for Oa subunit
than in premenopausal individuals.
Apart from malignancy, several other
clinical conditions have been shown to be
associated with increased serum oa subunit
levels. Excessive pituitary secretion of oa
subunit is found in primary hypothyroid-
ism (Kourides et al., 1975) and occasion-
ally patients with pituitary tumours have
increased oa subunit levels (MacFarlane
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et al., 1980b). In pregnancy, cx subunit is
secreted by the placenta (Vaitukaitis et
al., 1976) and patients with renal failure
also have high levels (tiagen et al., 1976).
None of the subjects in this study was
pregnant, no other disease was evident
and thyroid-function tests revealed no
trend towards hypothyroidism (MacFar-
lane et al., 1980a). Our finding of acute
increases in of subunit levels, presumably
originating from the pituitary, at the time
of ovulation agrees with another recent
study (Rosenberg & Bulat, 1979). In 5 of
our 21 premenopausal patients with cancer
who had high ax levels, LH and FSH con-
centrations measured in the same serum
sample were also high, suggesting recent
ovulation. Therefore the pituitary may
have contributed to the high of concentra-
tion in some of these premenopausal
patients.
It is of interest that 6/46 premeno-
pausal patients with benign disease had
high of levels and there was no significant
difference in ox concentrations between the
premenopausal patients with benign
disease and those with cancer. Only one
of these 6 benign patients had gonado-
trophin levels compatible with recent
ovulation. Recently other grouips have
also documented increases in a levels in
benign as well as malignant conditions
(Dosogne-Guerin et al., 1978; Braunstein
et al., 1979). These observations are at
variance with results of a study of
patients with pancreatic islet-cell tumours,
in which serum of subunit was high only in
malignant tumours, and normal in benign
cases (Kahn et al., 1977).
Patients with REc+ breast ttimours liave
a significantly better survival than those
who are REC- (Hcihnel et al., 1979) and
patients with advanced breast cancer and
REC± tumours respond better to hormonal
therapy than those who are negative
(Barnes et al., 1977). Knowledge of RPC
and REN status of the tumour- appears to
reinforce the precision with which the
response to hormone therapy may be pre-
dicted (Barnes et al., 1 979). However, the
role of REC status as an indicator of a
46
likely response to chemotherapy in ad-
vanced breast cancer patients is disputed
(Lippman et al., 1978; Kiang et al., 1978).
In this studv there was no statistical corre-
lation between of subunit levels and the
presence or absence of hormone receptors,
either individuallv or in combination
though there was a definite trend towards
higher a levels in those pre- and postmeno-
pausal patients who were REC- and RPC-.
In the premenopausal patients of levels
were higher in REN- patients than in
REN+ patients.
In premenopausal patients with cancer
a positive correlation between of subunit
levels and disease stage was found, but
not, however, in the postmenopausal
group. More advanced disease stage at
presentation is associated with a reduced
survival of patients with breast cancer
(Say et al., 1974), and therefore the high
levels of o subunit in premenopausal
patients at presentation with breast cancer
may indicate a worse prognosis.
In a study of patients with metastatic
melanoma, high pretreatment of subunit
levels in premenopausal women were asso-
ciated with a reduced survival and failure
to respond to chemo-immunotherapy
(MacFarlane et al., 1979). As all the
patients with melanoma were in the same
stage grouping, increased cx subunit levels
suggested a more malignant, uinresponsive
type of melanoma. However, in the pre-
menopausal patients with breast cancer
studied here, we are unable to assume that
high cx levels represent a more malignant
tumour; they may merely reflect a greater
tumour burden.
The use of x subunit as a tumour marker
appears limited. The increases in ax con-
centrations found in the patients with
breast cancer were usually moderate and
there was considerable overlap in serum
ax levels between the 3 groups (cancer,
benign and controls). Fluctuations of a,
level during the menstrual cycle reduce
the potential of serial measurements of
ax subunit for detecting early tumour
recurrence in premenopausal patients.
However, the strong correlation between650 I. A. MACFARI.ANE ET AL.
high of levels and more advanced disease
stage in premenopausal patients suggests
that a subunit measurement, preferably
several samples taken on different days
and related to concurrent LH and FSH
levels, may be a useful adjunct to more
accurate staging. Aids to the staging of
breast cancer are needed, as most patients
with regional nodes involved at the time
of mastectomy already have disseminated
disease (Bonnadonna et al., 1976). The
correlation of as subunit levels with subse-
quent response to a hormonal manipula-
tion or chemotherapy may form the basis
for further study, in view of the trend to-
wards increased of levels in patients with
REC- tumours.
I.A.M. was supported by a grant from the North
West Regional Health Authority during the course
ofthis work.
We thank NIAMDD National Pituitary Agency,
Baltimore, Maryland for the gift of oa TSH and its
antiserum. We are grateful to Mrs B. M. Cekalo for
typing the manuscript.
REFERENCES
BARNES, D. M., RIBEIRO, G. G. & SKINNER, L. G.
(1977) Two methods for measurement of oestra-
diol-17,B and progesterone receptors in human
breast cancer and correlation with response to
treatment. Eur. J. Cancer, 13, 1133.
BARNES, D. M., SKINNER, L. G. & RIBEIRO, G. G.
(1979) Triple hormone-receptor assay: A more
accurate predictive tool for the treatment of
advanced breast cancer. Br. J. Cancer, 40, 862.
BONADONNA, G., BRUSAMOLINO, E., VALAGUSSA, P.
& 8 others (1976) Combination chemotherapy as
an adjuvant treatment in operable breast cancer.
N. Engl. J. Med., 294, 405.
BRAUNSTEIN, G. D., FORSYTHE, A. B., RASOR, J. L.,
VAN SCOY-MOSHER, M. B., THOMSON, R. W. &
WADE, M. E. (1979) Serum glycoprotein hormone
alpha subunit levels in patients with cancer.
Cancer, 44, 1644.
COVE, D. H., SMITH, S. C. H., WALKER, R. &
HOWELL, A. (1979) The synthesis of glycoprotein
hormone a subunit by human breast carcinomas.
Eur. J. Cancer, 15, 693.
DOSOGNE-GUERIN, M., STALARCZYK, A. & BORKOW-
SKI, A. (1978) Prospective study of the a and P subunits of human chorionic gonadotrophin in the
blood of patients with various benign and malig-
nant conditions. Eur. J. Cancer, 14, 525.
HAGEN, C., GILBY, E. D., MCNEILLY, A. S.,
OLGAARD, K., BONDY, P. K. & REES, L. H. (1976)
Comparison of circulating glycoprotein hormones
and their subunits in patients with oat cell
carcinoma of the lung and uraemic patients on
chronic dialysis. Acta Endocrinol., 83, 26.
HXHNEL, R., WooDINGs, T. & VIVIAN, A. B. (1979)
Prognostic value of oestrogen receptors in
primary breast cancer. Cancer, 44, 671.
HARMER, M. H. (Ed.) (1978) Classification of malig-
nant tumour8, 3rd edition. Geneva: U.I.C.C.
KAHN, C. R., ROSEN, S. W., WEINTRAUB, B. D.,
FAJANS, S. S. & GORDON, P. (1977) Ectopic pro-
duction of chorionic gonadotrophin and its sub-
units by islet cell tumours. A specific marker for
malignancy. N. Engl. J. Med., 297, 565.
KIANG, D. T., FRENNING, D. H., GOLDMAN, A. I.,
AsCENSAO, V. F. & KENNEDY, M. D. (1978)
Oestrogen receptors and responses to chemo-
therapy and hormonal therapy in advanced breast
cancer. N. Engl. J. Med., 299, 1330.
KOURIDES, I. A., WEINTRAUB, B. D., RIDGWAY,
E. C. & MALOOF, F. (1975) Pituitary secretion of
free alpha and beta subunit of human thyro-
trophin in patients with thyroid disorders. J. Clin.
Endocrinol. Metabol., 40, 872.
LIPPMAN, M. E., ALLEGRA, J. C., THOMPSON, B. & 7
others (1978) The relation between oestrogen
receptors and response rate to cytotoxic chemo-
therapy in metastatic breast cancer. N. Engl. J.
Med., 298, 1223.
MACFARLANE, I. A., THATCHER, N., SWINDELL, R.,
BEARDWELL, C. G., HAYWARD, E. & CROWTHER,
D. (1979) Serum glycoprotein hormone alpha
subunit values and survival in metastatic melan-
oma patients. Eur. J. Cancer, 15, 1497.
MACFARLANE, I. A., ROBINSON, E. L., BUSH, H. & 4
others (1980a) Thyroid function in patients with
benign and malignant breast disease. Br. J. Cancer,
41, 478.
MACFARLANE, I. A., BEARDWELL, C. G., SHALET,
S. M., DARBYSHIRE, P. J., HAYWARD, E. &
SUTTON, M. L. (1980b) Glycoprotein hormone
oa subunit secretion by pituitary adenomas:
Influence ofexternal irradiation. Clin. Endocrinol.,
13, 215.
ROSENBERG, E. & BULAT, G. (1979) Immunoreactive
a and P subunits of FSH and LH in peripheral
blood throughout the menstrual cycle and follow-
ing stimulation with synthetic gonadotrophin
releasing hormone (GnRH). J. Endocrinol. Invest.,
2, 233.
SAY, C. & DONEGAN, W. L. (1974) Invasive carcin-
oma of the breast: Prognostic significance of
tumour size and involved axillary lymph nodes.
Cancer, 34, 468.
VAITUKAITIS, J. L., Ross, G. T., BRAUNSTEIN, G. D.
& RAYFORD, P. L. (1976) Gonadotrophins and
their subunits: Basic and clinical studies. Recent
Prog. Hormone Res., 32, 289.
WALKER, R. A. (1978) Significance of a subunit
HCG demonstrated in breast carcinomas by the
immunoperoxidase technique. J. Clin. Pathol., 31,
245.